Dr. Doherty's testosterone gynecomastia claims, fact-checked

Boston plastic surgeon Dr. Sean Doherty tells his 38,000 Instagram followers that testosterone can cause gynecomastia, but "it depends" on dosage and indication. He's mostly right about the basic mechanism, but his nuanced take glosses over some important details about aromatization and individual risk factors.

What does this video actually claim?

Doherty argues that testosterone's gynecomastia risk depends on how much you take and why you're taking it. He suggests therapeutic doses for legitimate hypogonadism carry less risk than supraphysiologic doses used for bodybuilding.

The claim sounds reasonable on its surface. Higher doses should theoretically increase aromatization to estradiol, which drives breast tissue development in men. But this oversimplifies the actual risk factors.

He doesn't mention baseline estradiol levels, aromatase enzyme activity, or body fat percentage. All these factors matter more than simple dose calculations when predicting who'll develop gynecomastia.

Does the science back this up?

The dose-dependent relationship isn't as clear-cut as Doherty suggests. A 2017 study by Finkelstein et al. in the Journal of Clinical Endocrinology found that estradiol levels, not testosterone doses, predicted breast tissue changes in healthy men.

The researchers gave 198 men varying testosterone doses with and without aromatase inhibitors. Gynecomastia occurred when estradiol exceeded 60 pg/mL, regardless of testosterone dose. Some men on 125mg weekly developed breast tissue while others on 300mg didn't.

Individual aromatase activity varies dramatically. Men with high aromatase can develop gynecomastia on 100mg testosterone weekly, while others tolerate 200mg without issues. Body fat percentage also matters since adipose tissue contains aromatase enzymes.

What did he get wrong?

Doherty's "why you're taking it" distinction doesn't hold up scientifically. Your body doesn't care whether testosterone comes from a prescription for hypogonadism or underground labs for bodybuilding.

What matters is total testosterone levels, aromatization rate, and estradiol management. A hypogonadal man taking 200mg weekly can develop gynecomastia just as easily as a bodybuilder on the same dose.

He also doesn't mention that gynecomastia can develop even with normal estradiol levels in some men. The 2019 study by Cuhaci et al. in Endocrine found that 12% of men with gynecomastia had normal hormone panels, suggesting other mechanisms beyond simple aromatization.

What should you actually know?

Testosterone-induced gynecomastia is real but not inevitable. The key is monitoring estradiol levels, not just focusing on testosterone doses. Most men need estradiol between 20-40 pg/mL to avoid both breast tissue growth and joint problems from too-low estrogen.

Aromatase inhibitors like anastrozole can prevent gynecomastia, but they're tricky to dose correctly. The 2016 study by Dias et al. showed that 0.25mg twice weekly was effective for most men, but some needed different frequencies.

If you're starting testosterone, get baseline labs including estradiol and prolactin. Recheck at 6 weeks and adjust accordingly. Don't wait for breast tissue to develop because established gynecomastia rarely resolves without surgery.